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  Abstract 
 Opioids have become a staple in the medical world as an analgesic used to treat 
acute and chronic pain.  However, there are many issues associated with the frequent use 
of opioids including tolerance, constipation, and opioid-induced hyperalgesia.  
Fortunately, recent discoveries of neuropeptide FF (NPFF) antagonists, have led to the 
understanding that tolerance and hyperalgesia caused by opioids can be greatly reduced.  
This discovery eventually led to the creation of dual ligands with both opioid agonist and 
NPFF antagonist activity.  These dual ligands have been shown to prevent tolerance and 
opioid-induced hyperalgesia while maintain analgesic qualities in mice.  However, these 
studies have involved injecting the drug directly into the brain due to their inability to 
cross the blood brain barrier, which makes them unfit to be converted into drugs fit for 
clinical use.  Intravenous or intraperitoneal injection routes can be used but, oral 
administration would be the best option for therapeutic use.  With this goal in mind, we 
are met with the task of having the drug penetrate the blood-brain barrier so that it may 
reach the appropriate recepetors.  In this study, we had modified the lead small molecule 
(non-4,5α-epoxymorphinan derived) designated multiple ligands to hopefully have such 
blood-brain barrier penetration capabilities.  We will evaluate the antinociception of these 
compounds to determine if they have successfully reached their target receptors from 
peripheral administration.  These compounds tested represent only a portion of the 
compounds created by our lab.  
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1	  
Introduction 
 Prescription drugs such as hydrocodone and oxycodone, µ-opioid receptor 
agonists, are popular opioid analgesics used to treat acute and chronic pain.  While 
serving as excellent analgesics, these opioids have a host of problems associated with 
their use, particularly when dealing with long-term pain treatment.  Prolonged use of 
opioids may result in a phenomenon known as tolerance.  In tolerance, the opioid 
receptors become acclimated to the constant intake of opioids and the body shuts down 
its own natural (endogenous) production of opioids in anticipation of receiving more 
external opioids.  As a result, a higher dose of opioids is required to achieve the same 
desired effect that was previously experienced and the opioid receptors reach a point 
where they are rendered essentially non-functional. 
 Neuropeptide FF (NPFF) receptors have been identified as an antiopioid or 
pronociceptive system, essentially working opposite to opioid receptors.  Whereas 
opioids reduce pain, neuropeptide FF causes pain as a protection mechanism when 
released by itself.  If the body is not producing endogenous opioids, it is relying on 
exogenous opioids to act in its place.  However, when we stop taking those exogenous 
opioids, only neuropeptide FF is being produced.  This release of neuropeptide FF 
without an opioid countermeasure results in increased sensitivity to pain, as a result of 
not taking exogenous opioids, is known as opioid-induced hyperalgesia.  To prevent the 
release of NPFF in the absence of opioids, it is necessary to have an antagonist acting on 
the NPFF receptors.
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While the entire NPFF system is generally accepted to be an antiopioid system, 
the two subtypes, NPFF1-R and NPFF2-R, appear to have possibly conflicting 
effects.The NPFF1-R subtype has been well defined as an antiopioid receptor as shown 
by in vivo activity of NPFF1-selective dipeptide antagonists (Figure 1-2).  But, the 
NPFF2-R subtype remains doubtful due to a lack of selective ligands specific to it.  Tests 
have shown that NPFF-2R may actually have a pro-opioid effect contrary to the 
classification of the NPFF system.  However, even these claims are speculative because 
of the weakness of the tests performed.  Fortunately, Simonin et al. (2006) discovered 
that the binding affinity of non-selective dipeptide NPFF antagonist RF9 (Figure 1-1) 
may be influenced by both subtypes, which suggests that NPFF2-R may also an 
antiopioid receptor.  Even if both subtypes were to be antiopioid in nature, the lack of 
receptor ligands makes attaining good affinity for NPFF receptors troublesome to obtain.  
Fortunately, the non-selective binding affinity of RF9 to both subtypes makes it a good 
candidate to be a potent NPFF antagonist. 
Figure 1. 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
1. RF9, non-selective antagonist                  2. NPFF1-R selective dipeptide antagonist 
Through the co-administration of RF9 and heroin, a µ opioid agonist, the overall 
drug effects resulted in improved analgesic activity while successfully preventing 
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tolerance, opioid-induced hyperalgesia, and reducing other related opioid side effects.  
RF9, as an independent drug (separate from the µ opioid agonist but administered 
simultaneously), only prevents the development of tolerance and does not cure pre-
existing tolerance.  It has been hypothesized that a NPFF antagonist with dual opioid 
agonist activity could resolve this issue (this will be discussed later).  Clinically, this is 
also much more appealing because of reduced patient drug intake, better drug efficacy, 
and a lower risk of drug-drug interactions. 
Returning to RF9 as a NPFF antagonist, RF9 has been found to have good affinity 
as a NPFF antagonist because of its chemical structure and composition.  Good NPFF 
antagonists have at minimum a phenyl and a guanidine component.  Optimally, the 
chemical compound should contain a C-terminal amide, the guanidine portion of an 
arginine group, and the aromatic ring (more specifically the benzene group) of a 
phenylalanine group in order to achieve maximum NPFF receptor affinity.  The 
guanidine group is intended to mimic arginine interaction and the aromatic ring/benzene 
group is meant to mimic the phenylalanine group.  These substitutions are intended to 
reduce the overall size and molecular weight of the drug so that it may be more 
bioavailable. 
Based on these conditions, Journigan et. al (2014) discovered that (Figure 2-1) 
makes a good starting template for creating an optimal NPFF antagonist.  Not only does 
this NPFF-binding guanidino-piperidine template retain the desired molecular elements, 
it has good chemical feasibility and is rather flexible.  The piperidine nitrogen component 
allows for lipophilic substitutions to be made.  An additional goal accomplished by 
creating this template was creating a non-peptide NPFF antagonist.  Peptides are easily 
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cleaved by peptidases and they have too short of an action.  Because it is a non-peptide 
small molecule, this template allows for good chemical stability, bioavailability, and 
duration of action.  From this template, a NPFF1-R selective antagonist (Figure 2-2) was 
also proposed by the group.  Tests have shown that it has successfully prevented opioid-
induced hyperalgesia. 
Figure 2.   
	  
1. 4-(Phenylamino)piperidine-4-carbonitrile scaffold 
	  
 
2. NPFF1-R selective antagonist 
Now that we have our desired NPFF antagonist, we are now met with the 
challenge of combining an opioid agonist and a NPFF antagonist into a dual-activity drug 
(better known as a designed multiple ligand [DML]) while still maintaining both the 
analgesic effect and the removal of tolerance and hyperalgesia.  To achieve this, the drug 
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must have an affinity for both the opioid receptors and the NPFF receptors.  Prior 
attempts at achieving a dual-activity drug have resulted in DMLs with bioavailability 
issues because of their high molecular weight and multiple peptide bonds.  However, 
Journigan et. al have described small molecule non-4,5α-epoxymorphinan derived DMLs 
(Figure 3-3) that act as both an opioid agonist and a NPFF antagonist. 
In order to create this dual-activity drug, we need to take the important portion of 
a NPFF antagonist and combine it with the relevant portion of an opioid agonist.  Our 
research group suggested that the dual-activity drug be based on an opioid scaffold with a 
1,4-disubstituted piperidine core with at least one phenyl ring at the 4-position.  The 
NPFF1-R antagonist used would be the antagonist created by the group (Figure 3-1) and 
the opioid agonist (and also the starting point the drug) to be used would be the delta-
opioid agonists BW373U86 and SNC80 (Figure 3-2).  This agonist was chosen because 
the previously created guanidine-piperidine template tolerates the phenyl ring on the 
diarylmethylidene piperidine portion of the agonist.  The 4-N,N-diethylaminocarbonyl 
group of the agonists was replaced with a NPFF pharmacophoric guanidine group.  This 
not only gives the drug increased NPFF receptor affinity, it also reduces the delta opioid 
selectivity of the drug (as we desire µ selectivity).  The hydroxyl group was kept because 
it was hypothesized that it could mimic the tyrosine residue Tyr-Gly-Gly-Phe message 
sequence present in endogenous opioid peptides.  To further increase NPFF receptor 
affinity, a benzyl group was inserted into the N-1 position.  The resulting molecule is 
shown in Figure 3-3. 
 
 
6	  
	  
Figure 3. 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  
        1. NPFF1-R antagonist                                              2. Delta-opioid agonist         
      R = OH, H 
R1 = aliphatic, cyclic, aromatic 
groups 
	  
	  
3. Opioid/NPFF Merged DML 
In the same study performed to create the DML, the molecules’ receptor affinity 
and functional activity were also evaluated.  We are interested in comparing the changes 
in receptor affinity and activity between the DML (Figure 3-3) and the NPFF1-R 
antagonist (Figure 3-1).  In Figures 4 and 5, the antagonist is compound 30a and the 
DML is compound 18b.  The antagonist starts off with decent NPFF1-R affinity, very 
strong NPFF2-R binding, and weak opioid binding.  The DML maintains its overall 
R1
N
R
O
N
N
OH
HN
HN NH2
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NPFF affinity, except for NPFF2-R which may not be as important, indicating that it may 
still possess its antagonistic activity.  On the other hand, it gains a lot of opioid binding 
affinity, but it is still comparatively weak compared to the other compounds.  However, 
this is good as the DML maintains NPFF affinity while gaining significant opioid 
affinity. 
Figure 4. 
 
	   	   	   	   Receptor	  Binding,	  Ki	  (nM)	  
Cmpd.	   R	   R1	   NPFF1-­‐R	   NPFF2-­‐R	   µ δ κ 
17a	   3-­‐	   3'-­‐OH	   311	  ±	  13	   909	  ±	  73	   2.9	  ±	  0.3	   12	  ±	  2	   2.4	  ±0.2	  
18a	   3-­‐	   4'-­‐OH	   570	  ±	  161	   4134	  ±	  392	   13	  ±	  2	   19	  ±	  2	   15	  ±	  2	  
17b	   4-­‐	   3'-­‐OH	   1061	  ±	  94	   707	  ±	  6	   16	  ±	  3	   7.2	  ±	  0.9	   3.2	  ±	  0.3	  
18b	   4-­‐	   4'-­‐OH	   935	  ±	  46	   1251	  ±	  110	   116	  ±	  23	   76	  ±	  19	   3.3	  ±	  0.4	  
29a	   3-­‐	   H	   314	  	   534	  	   4.7	  ±	  0.6	   38	  ±	  5	   23	  ±	  12	  
30a	   4-­‐	   H	   976	  	   106	  	   340	  ±	  40	   230	  ±	  30	   140	  ±	  10	  
 
NPFF and Opioid Receptor Binding Affinity of the Compounds 
 As for the functional activity, we see that all of the compounds possess significant 
NPFF antagonist activity.  The NPFF1-R antagonist also possesses a lot of opioid agonist 
activity, but it is not as µ-selective as we would like it to be.  Fortunately, the DML 
continues to possess both NPFF antagonist and opioid agonist activity as well as focusing 
its opioid activity on the µ receptor.  Overall, the changes made to create the DML 
resulted in relatively good receptor binding to both NPFF and opioids receptors.  As a 
result, the DML also exhibited good NPFF activity and good µ-opioid activity. 
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Figure 5. 
 
NPFF and Opioid Functional Activity of the Compounds 
While studies have demonstrated that dual-activity opioid-NPFF ligands 
successfully block tolerance and opioid-induced hyperalgesia while maintaining 
analgesic effects, the synthesized drugs used have only been directly injected into the 
brain.  Clinically, it would be unrealistic to directly inject a drug into a patient’s brain on 
a consistent basis.  Optimally, we would want for the drug to be administered through 
intravenous or intraperitoneal injection or even through oral administration.  The key 
issue is modifying the drug so that it will be able to permeate through the blood-brain 
barrier to reach the appropriate receptors.  In this experiment, we are not as concerned 
with preventing tolerance or hyperalgesia as we are with observing antinociception to 
ensure that the drug has reached the brain. 
We initially avoided the use of peptides by adding a guanidine group to our drug 
to make it more stable and to help it last longer.  The problem now is that guanidine has a 
positive charge associated with it which makes it very basic in nature.  Consequently, 
guanidine does not cross membranes, like the blood-brain barrier, very well.  However to 
work effectively, the drug requires at least two nitrogen groups (guanidine provides three 
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of them); so the drug must be modified around guanidine rather than removing it 
completely. 
The concept of optimizing brain penetration is centered on the 5-
Hydroxytryptamine (5-HT) (particularly the 5-HT5AR subtype) receptor, lipophilicity, 
and pH.  Selective 5-HT5AR receptor antagonists have shown to have good antipsychotic-
like potential and have become a target of interest for drugs.  Tests with a guanidine-type 
5-HT5AR antagonist (Figure 6-1) shows high affinity to the receptor as well as a modest 
brain penetration.  Brain penetration is optimized when the drug is highly lipophilic (high 
logD) and when basicity is low.  Peters et. al (2007) found that fluoro-ethyl substituents 
substantially improve lipophilicity and reduce basicity of the guanidine.  Further 
experiments determined that difluoroethyl is the superior flouro-ethyl substituents as its 
insertion as a side chain into the compound led to high activity, reduced basicity, and 
improved lipophilicity with minimal reduction in 5-HT5AR receptor affinity (Figure 6-2). 
Figure 6.  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	    
              1. 5-HT5AR antagonist                                 2.Difluoroethyl substituent  
Based on these findings, we can modify the compound that Journigan et. al 
synthesized (Figure 7-1) and optimize its brain penetration.  One way to do this is to 
replace one of guanidine’s nitrogen groups with a difluoroethyl group (Figure 7-3).  This 
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produces a similar effect by reducing the basicity of guanidine enough to allow it to pass 
through the blood-brain barrier.  Another less effective method is to replace guanidine 
with amidine (Figure 7-2), which is similar in structure to guanidine minus one nitrogen 
group.  While still basic in nature, the removal of one nitrogen group has been proven to 
reduce the drug’s basicity enough for it to cross the blood-brain barrier.   
Figure 7. 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
1. Opioid/NPFF Merged DML                                  2. DML w/amidine	  
	   	  
3. DML w/ difluoroethyl substituent
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Materials and Methods 
 For this experiment, black C57BL6 mice from Harlan Laboratories were used as 
test subjects; mice were tested on in groups of eight.  In order to measure antinociception, 
the mice were put through an organized regimen of trials and injection.  The amount of 
drug given to each mouse was dependent on their weight in grams.  For every one gram 
the mouse weighed, 0.1 mL of drug was injected into the mouse.  The drug was injected 
intraperitoneally to determine if the drug could travel to the brain by permeating through 
the blood-brain barrier. 
The three drugs tested in vivo were CNK404 (Figure 8-1), CNK406 (Figure 8-2), 
and CNK408 (Figure 8-3).  A vehicle drug, a mixture of ethanol, cremophor, and saline 
(1:1:18), was used for baseline measurements and as the base for dissolving the drugs to 
be tested.  Morphine was also tested as a positive control.  Each drug was tested three 
times in varying doses of 5 mg/kg, 10 mg/kg, and 20 mg/kg, except for morphine which 
was only tested in a 10 mg/kg dose.  It is important to note that the biding affinities for 
NPFF and opioids receptors have not yet been obtained in these three drugs. 
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Figure 8. 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
1. CNK404                                              2. CNK406 
 
3. CNK408 
There were two different assays that were used in determining the impact of the 
drugs on the mice.  One was the hotplate assay and the other was the tail-flick assay.  
These assays were designed to test how quickly (in seconds) the mice will react to pain 
stimulation (in this case intense heat), thus testing the analgesic effects of the drugs.  The 
hotplate assay is designed to demonstrate a conscious awareness of pain, similar to 
stepping barefoot onto hot asphalt.  The tail-flick assay is designed to measure a reflex 
action to pain, similar to touching a flame or an extremely hot burner.  These two assays 
represent measurements of supraspinal (hotplate) and spinal (tail-flick) analgesia. 
N
NH2
NH
N
NH2
NH
O
N
NH2
N
HO
OH
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Before experimentation, a baseline reading for antinociception was taken for 
future comparison.  After a baseline assessment using the hotplate and tail-flick assay, the 
mice were immediately injected with the designated drug.  The mice were allowed to sit 
for 30 minutes so that the drug would have a chance to travel to its target location, the 
receptors in the brain.  After 30 minutes, the mice were assessed again using the same 
hotplate and tail-flick assay. 
 The hotplate assay is used to examine the effects of the drug on thermal 
nociception.  This assay utilizes a hotplate machine that maintains a constant heat level 
and a plexiglass cylinder to ensure that the mouse is continuously exposed to the heat and 
is able to be clearly observed.  A timer is manually started once all four paws of the 
mouse make contact with the hotplate.  The timer is stopped when a reaction to the heat is 
noticed on the hindpaws including jumping, toe curling, rapid tapping, and paw-licking.  
To prevent tissue damage, we have established cut-off periods in which we stop the trial 
even if we do not see a reaction.  The overall cut-off period is 45 seconds.  Only one trial 
of the hotplate assay is performed each time. 
 The tail-flick assay also examines thermal nociception using a special apparatus.  
The apparatus works by shining a concentrated beam of light at the mouse’s tail and then 
recording how long it takes for the mouse to react in response to pain.  To prevent 
unnecessary movements, the mouse’s body is confined within a restrainer with only the 
tail exposed and free to move.  The tail is positioned over a groove on the apparatus 
where the thermal stimulus is to be applied.  The thermal stimulus is simultaneously 
activated along with an automated response timer.  When the mouse flicks his tail, the 
beam of light is broken and both the thermal stimulus and the timer are stopped.  Two 
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trials are taken approximately 20 to 30 seconds apart from each other.  The cut-off period 
before drug injection is 5 seconds.  If the mouse does not react to 5 second thermal 
stimulus twice, that mouse is unable to be utilized for that experiment.  The cut-off period 
after drug injection is 15 seconds.  If the mouse exceeds 10 seconds on the first of two 
trials, it is not necessary to run a second trial. 
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Results and Discussion 
The hotplate and tail-flick data for the three drugs and morphine were compared 
to the vehicle drug primarily through mean value +/- SEM (standard error of the mean or 
standard deviation) of % MPE (percent maximum effect). 
The %MPE equation for the tail-flick assay is: 
%  𝑀𝑃𝐸 =   𝑝𝑜𝑠𝑡𝑑𝑟𝑢𝑔  𝑙𝑎𝑡𝑒𝑛𝑐𝑦   𝑠 − 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒  𝑙𝑎𝑡𝑒𝑛𝑐𝑦(𝑠)15  𝑠𝑒𝑐𝑜𝑛𝑑𝑠 − 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒  𝑙𝑎𝑡𝑒𝑛𝑐𝑦  (𝑠) ∗ 100% 
 
The %MPE equation for the hotplate assay is: 
%𝑀𝑃𝐸 =   𝑝𝑜𝑠𝑡𝑑𝑟𝑢𝑔  𝑝𝑎𝑡𝑒𝑛𝑐𝑦   𝑠 − 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒  𝑙𝑎𝑡𝑒𝑛𝑐𝑦(𝑠)𝑐𝑢𝑡  𝑜𝑓𝑓  𝑡𝑖𝑚𝑒   45  𝑠 − 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒  𝑝𝑎𝑡𝑒𝑛𝑐𝑦  (𝑠) ∗ 100% 
 
The %MPE obtained from the experiments was analyzed using GraphPad Prism 
and used to calculate the mean value +/- SEM for each drug and dose.  Using a one-way 
ANOVA, preceded by the Dunnett’s post hoc test, the mean values +/- SEMs for the 
three drugs and morphine were analyzed for statistical significance against the vehicle 
control at p < 0.05.  Separate analyses were performed for the hotplate and the tail-flick 
assays. 
Figure 9 below shows the average %MPE for the vehicle drug, morphine, and 
three drugs tested for the tail-flick assay.  From the statistical analysis, none of the three 
drugs were found to be statistically significant from the vehicle drug at all three doses.  
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Morphine, on the other hand, was found to have high statistical significance.  
Increasing the dose may have a small effect on increasing the antinociception of the 
CNK404 drug but it has no apparent effect on the other two drugs.  The antinociception 
of the drugs in regards to the tail-flick assay are effectively absent in comparison to both 
the vehicle drug and morphine. 
Figure 9. 
 
Comparison of tail-flick %MPE between CNK drugs, morphine, and vehicle drug 
 
Figure 10 below shows the average %MPE for the vehicle drug, morphine, and 
the three drugs tested for the hotplate assay.  The CNK404 drug looked promising at first 
glance as it exceeded the vehicle drug %MPE, but further analysis showed that it was 
statistically insignificant.  However, the increasing dose and antinociception correlation is 
still present in CNK404 but not in the other two drugs.  Just like in the tail-flick assay, 
none of the three drugs showed statistical significance while morphine showed high 
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statistical significance.  Unfortunately, this means that antinociception remains 
absent in regards to the hotplate assay. 
Figure 10. 
 
Comparison of hotplate %MPE between CNK drugs, morphine, and vehicle drug 
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Conclusion 
 Based on the results gathered from the experiment, all three CNK drugs are not 
active at these dosage levels.  Using morphine as a comparison, we are still far from 
achieving the antinociception that we desire from these drugs.  The CNK404 drug looked 
promising because of the subsequent increase in %MPE with increasing dose, but more 
research must be conducted to determine the strength and accuracy of that perceived 
correlation.  The remaining two drugs have no consistency nor patterns that come from 
increasing the dose.   
 Several things could have happened for the drug to not work.  While it is fairly 
certain that the drug did not penetrate the brain, we cannot definitively say that until we 
further examine the pharmacodynamics of the drugs.  Assuming that the compounds did 
not penetrate the brain, the modifications to the original small molecule non-4,5α-
epoxymorphinan derived DMLs (Figure 3-3) structure did not actually improve brain 
penetration enough or at all.  On the other hand, if the drug did in fact penetrate the brain, 
more possibilities arise.  The drug dose may not have been high enough for the drug to 
show analgesic effects, the drug may not have bound to the proper receptors (or bound to 
the proper receptors too weakly), or perhaps the drug failed to bind to a receptor at all. 
Also, we should consider the possible pharmacokinetics of the drug.  Two 
parameters that may present issues are half-life and maximum concentration (Cmax).  It 
typically takes about five half-lives for a drug to reach its steady-state concentration so
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the timing between pre- and post-injection evaluations is critical in finding that 
concentration.  If we are too early, the drug will not have any efficacy yet; if we are too 
late, the drug will have been eliminated from circulation.  Cmax is also important because 
we need to find the proper concentration between toxic and therapeutic levels.  It is 
important to find a proper balance so that the drug will be as effective as possible. 
 Conclusions drawn from this experiment are limited by the nature of the 
experiment.  The experiment was only designed to test whether or not the drug has 
antinociception potential (and to what degree) and did not explore the chemistry of the 
compounds.  The only thing that we can confidently conclude from this experiment is 
that the CNK drugs are not active at these particular doses.  Until we further explore the 
chemistry of the drugs, the other conclusions are mere speculation as to why the 
compounds failed.  However based on previous findings, the most likely explanation 
remains:  the drugs did not penetrate the brain and need to be further optimized in order 
to be active as an analgesic. 
 There are still many things that can be done to possibly improve the brain 
penetration of the dual-activity ligands.  The simplest way is to change the dosage of the 
drugs and see if there is a correlation between dose and brain penetration at varying doses 
as well as helping us to discover an optimal Cmax.  We can also adjust the wait time in-
between pre- and post-injection evaluations to see if we can discover the half-life of the 
drug and consequently discover the amount of time it takes for the take to exhibit full 
efficacy.  We can also continue to optimize the drug by further manipulating the original 
compound, though there are no specific considerations at this time.  We could also 
improve our current assays or expand upon our repertoire of assays in order to obtain 
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more accurate measures of antinociception.  Our group is working on creating more 
compounds and we continue to be optimistic about the antinociception potential of these 
drugs. 
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